MacroGenics, Inc. (MGNX)
NASDAQ: MGNX · Real-Time Price · USD
1.730
-0.020 (-1.14%)
At close: Feb 4, 2026, 4:00 PM EST
1.700
-0.030 (-1.73%)
After-hours: Feb 4, 2026, 4:25 PM EST
MacroGenics Revenue
MacroGenics had revenue of $72.84M in the quarter ending September 30, 2025, a decrease of -34.21%. This brings the company's revenue in the last twelve months to $127.63M, down -9.70% year-over-year. In the year 2024, MacroGenics had annual revenue of $149.96M with 155.26% growth.
Revenue (ttm)
$127.63M
Revenue Growth
-9.70%
P/S Ratio
0.86
Revenue / Employee
$374,270
Employees
341
Market Cap
109.44M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 149.96M | 91.21M | 155.26% |
| Dec 31, 2023 | 58.75M | -93.19M | -61.33% |
| Dec 31, 2022 | 151.94M | 74.49M | 96.19% |
| Dec 31, 2021 | 77.45M | -27.44M | -26.16% |
| Dec 31, 2020 | 104.88M | 40.70M | 63.40% |
| Dec 31, 2019 | 64.19M | 4.07M | 6.76% |
| Dec 31, 2018 | 60.12M | -97.62M | -61.89% |
| Dec 31, 2017 | 157.74M | 65.86M | 71.68% |
| Dec 31, 2016 | 91.88M | -8.97M | -8.90% |
| Dec 31, 2015 | 100.85M | 53.06M | 111.00% |
| Dec 31, 2014 | 47.80M | -10.24M | -17.64% |
| Dec 31, 2013 | 58.04M | -5.79M | -9.07% |
| Dec 31, 2012 | 63.83M | 6.62M | 11.57% |
| Dec 31, 2011 | 57.21M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Karyopharm Therapeutics | 142.53M |
| Codexis | 52.93M |
| Spero Therapeutics | 40.55M |
| Verrica Pharmaceuticals | 30.83M |
| Korro Bio | 7.37M |
| Cardiff Oncology | 501.00K |
| Inovio Pharmaceuticals | 182.34K |
| Genelux | 8.00K |
MGNX News
- 2 months ago - MacroGenics to Participate in the 8th Annual Evercore Healthcare Conference - GlobeNewsWire
- 3 months ago - MacroGenics Reports Third Quarter 2025 Financial Results and Provides Update on Corporate Progress - GlobeNewsWire
- 3 months ago - MacroGenics to Participate in the Stifel 2025 Healthcare Conference - GlobeNewsWire
- 5 months ago - MacroGenics to Present at H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 6 months ago - MacroGenics Reports Second Quarter 2025 Financial Results and Highlights Key Strategic Priorities - GlobeNewsWire
- 6 months ago - MacroGenics Appoints Eric Risser as President and Chief Executive Officer - GlobeNewsWire
- 8 months ago - MacroGenics: Working On That Road To Recovery - Seeking Alpha
- 8 months ago - MacroGenics and Sagard Healthcare Partners Enter into ZYNYZ® Royalty Purchase Agreement - GlobeNewsWire